Similar articles for PMID: 31171752

Year	Number of Results
2005	1
2007	3
2008	1
2009	3
2010	2
2011	2
2012	5
2013	5
2014	16
2015	19
2016	22
2017	19
2018	26
2019	34
2020	35
2021	26
2022	22
2023	12
2024	0

1

[New Complement Therapeutics in Complement-Related Diseases].

Wakamiya N, Ohtani K, Hidaka Y, Inoue N. Wakamiya N, et al. Brain Nerve. 2019 Jun;71(6):555-564. doi: 10.11477/mf.1416201316. Brain Nerve. 2019. PMID: 31171752 Review. Japanese.

2

Current and future pharmacologic complement inhibitors.

Risitano AM. Risitano AM. Hematol Oncol Clin North Am. 2015 Jun;29(3):561-82. doi: 10.1016/j.hoc.2015.01.009. Epub 2015 Apr 4. Hematol Oncol Clin North Am. 2015. PMID: 26043392 Review.

3

Anticomplement C5 therapy with eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.

Wong EK, Kavanagh D. Wong EK, et al. Transl Res. 2015 Feb;165(2):306-20. doi: 10.1016/j.trsl.2014.10.010. Epub 2014 Oct 20. Transl Res. 2015. PMID: 25468487 Review.

4

Drugs that inhibit complement.

Schrezenmeier H, Höchsmann B. Schrezenmeier H, et al. Transfus Apher Sci. 2012 Feb;46(1):87-92. doi: 10.1016/j.transci.2011.11.012. Epub 2011 Dec 13. Transfus Apher Sci. 2012. PMID: 22169380 Review.

5

Eculizumab and Beyond: The Past, Present, and Future of Complement Therapeutics.

Patriquin CJ, Kuo KHM. Patriquin CJ, et al. Transfus Med Rev. 2019 Oct;33(4):256-265. doi: 10.1016/j.tmrv.2019.09.004. Epub 2019 Oct 22. Transfus Med Rev. 2019. PMID: 31703946 Review.

6

Small-molecule factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.

Yuan X, Gavriilaki E, Thanassi JA, Yang G, Baines AC, Podos SD, Huang Y, Huang M, Brodsky RA. Yuan X, et al. Haematologica. 2017 Mar;102(3):466-475. doi: 10.3324/haematol.2016.153312. Epub 2016 Nov 3. Haematologica. 2017. PMID: 27810992 Free PMC article.

7

Eculizumab in pregnancy: a narrative overview.

Sarno L, Tufano A, Maruotti GM, Martinelli P, Balletta MM, Russo D. Sarno L, et al. J Nephrol. 2019 Feb;32(1):17-25. doi: 10.1007/s40620-018-0517-z. Epub 2018 Aug 29. J Nephrol. 2019. PMID: 30159857 Review.

8

Safety and effectiveness of eculizumab for pediatric patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance.

Ito S, Hidaka Y, Inoue N, Kaname S, Kato H, Matsumoto M, Miyakawa Y, Mizuno M, Okada H, Shimono A, Matsuda T, Maruyama S, Fujimura Y, Nangaku M, Kagami S. Ito S, et al. Clin Exp Nephrol. 2019 Jan;23(1):112-121. doi: 10.1007/s10157-018-1610-2. Epub 2018 Jul 23. Clin Exp Nephrol. 2019. PMID: 30039480 Free PMC article.

9

Therapeutic complement inhibition – from experimental to clinical medicine.

Lappegård KT, Bjerre A, Tjønnfjord GE, Mollnes TE. Lappegård KT, et al. Tidsskr Nor Laegeforen. 2015 Oct 20;135(19):1745-9. doi: 10.4045/tidsskr.15.0049. eCollection 2015 Oct 20. Tidsskr Nor Laegeforen. 2015. PMID: 26486669 Free article. Review. English, Norwegian.

10

Anti-complement Treatment for Paroxysmal Nocturnal Hemoglobinuria: Time for Proximal Complement Inhibition? A Position Paper From the SAAWP of the EBMT.

Risitano AM, Marotta S, Ricci P, Marano L, Frieri C, Cacace F, Sica M, Kulasekararaj A, Calado RT, Scheinberg P, Notaro R, Peffault de Latour R. Risitano AM, et al. Front Immunol. 2019 Jun 14;10:1157. doi: 10.3389/fimmu.2019.01157. eCollection 2019. Front Immunol. 2019. PMID: 31258525 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

211 results

Results by year